Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) Price & Analysis

Compare

2 Followers

JAGSNPHARM Stock Chart & Stats

₹193.50

-₹13.50(-5.18%)

At close: Jan 08 4:00 PM EST

₹193.50

-₹13.50(-5.18%)

Day’s Range― - ―

52-Week Range₹154.90 - ₹301.80

Previous CloseN/A

Volume94.85K

Average Volume (3M)3.85K

Market Cap

₹12.14B

Enterprise Value₹12.08B

Total Cash (Recent Filing)₹1.59B

Total Debt (Recent Filing)₹88.36M

Price to Earnings (P/E)28.8

Beta1.07

Next Earnings

May 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.24%

Share Statistics

EPS (TTM)1.64

Shares Outstanding66,890,450

10 Day Avg. Volume3,534

30 Day Avg. Volume3,854

Financial Highlights & Ratios

PEG Ratio0.18

Price to Book (P/B)6.09

Price to Sales (P/S)5.44

P/FCF Ratio26.60

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue & Margin StrengthConsistent revenue growth alongside healthy gross and net profit margins and expanding EBIT/EBITDA margins indicates durable product competitiveness and efficient cost structure. This supports sustainable internal reinvestment, protects profitability through cycles, and underpins long-term cash generation.

Solid Balance SheetA strong equity-funded asset base and low leverage materially reduce financial risk, increase resilience to shocks, and preserve strategic optionality for capex or M&A. This durable capital structure supports steady operations and long-term investment without heavy dependence on external financing.

Cash GenerationReliable conversion of earnings into operating and free cash flow enables sustained reinvestment in the business, potential dividend payouts, and debt servicing. Strong cash generation is a lasting advantage in pharmaceuticals where funding R&D, working capital and manufacturing needs matters over multi-quarter horizons.

Bears Say

Declining LiquidityA decline in cash and short-term investments reduces the company's buffer for working capital, regulatory compliance costs, or unexpected supplier and receivable timing swings. Over months this can pressure flexibility, increase reliance on external funding, and raise execution risk for growth initiatives.

EPS ContractionA material negative EPS growth rate signals earnings pressure that may reflect product mix shifts, pricing headwinds, or cost increases. If persistent, falling EPS undermines reinvestment capacity and shareholder returns, and may indicate structural margin challenges rather than a short-term blip.

Concentration & Disclosure GapsReliance on domestic branded formulations and lack of product-level revenue disclosure create concentration and transparency risks. This limits visibility into which brands drive growth and hampers assessment of diversification or export opportunities, increasing long-term execution risk.

Jagsonpal Pharmaceuticals Ltd. News

Jagsonpal Pharma Discloses Rs 4.82 Crore Tax Demand, Plans Appeal

The latest announcement is out from Jagsonpal Pharmaceuticals Ltd. ( ($IN:JAGSNPHARM) ). Jagsonpal Pharmaceuticals Ltd. has disclosed that...

7d ago

Jagsonpal Pharma Grants 1.15 Million Stock Options Under ESOP 2022

The latest update is out from Jagsonpal Pharmaceuticals Ltd. ( ($IN:JAGSNPHARM) ). Jagsonpal Pharmaceuticals Ltd. has approved the...

12d ago

Jagsonpal Pharmaceuticals Allots ESOP Shares, Ups Paid-Up Capital

An announcement from Jagsonpal Pharmaceuticals Ltd. ( ($IN:JAGSNPHARM) ) is now available. Jagsonpal Pharmaceuticals has allotted 71,800 equity...

12d ago

Jagsonpal Pharma Publishes Unaudited Q3 and Nine-Month FY25 Results Extracts

Jagsonpal Pharmaceuticals Ltd. ( ($IN:JAGSNPHARM) ) has shared an update. Jagsonpal Pharmaceuticals Ltd. has published newspaper advertisements in...

2M ago

Jagsonpal Pharma Board Approves Unaudited Q3 and Nine-Month FY25 Results

Jagsonpal Pharmaceuticals Ltd. ( ($IN:JAGSNPHARM) ) has provided an update. Jagsonpal Pharmaceuticals Ltd. announced that its Board of...

2M ago

Jagsonpal Pharmaceuticals Schedules Analyst and Investor Meeting

Jagsonpal Pharmaceuticals Ltd. ( ($IN:JAGSNPHARM) ) has shared an announcement. Jagsonpal Pharmaceuticals Ltd. has announced a scheduled meeting...

4M ago

JAGSNPHARM FAQ

What was Jagsonpal Pharmaceuticals Ltd.’s price range in the past 12 months?

Jagsonpal Pharmaceuticals Ltd. lowest stock price was ₹154.90 and its highest was ₹301.80 in the past 12 months.

What is Jagsonpal Pharmaceuticals Ltd.’s market cap?

Jagsonpal Pharmaceuticals Ltd.’s market cap is ₹12.14B.

When is Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date?

Jagsonpal Pharmaceuticals Ltd.’s upcoming earnings report date is May 26, 2026 which is in 66 days.

How were Jagsonpal Pharmaceuticals Ltd.’s earnings last quarter?

Jagsonpal Pharmaceuticals Ltd. released its earnings results on Jan 21, 2026. The company reported ₹1.64 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.64.

Is Jagsonpal Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Jagsonpal Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Jagsonpal Pharmaceuticals Ltd. pay dividends?

Jagsonpal Pharmaceuticals Ltd. pays a Annually dividend of ₹2.5 which represents an annual dividend yield of 1.24%. See more information on Jagsonpal Pharmaceuticals Ltd. dividends here

What is Jagsonpal Pharmaceuticals Ltd.’s EPS estimate?

Jagsonpal Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Jagsonpal Pharmaceuticals Ltd. have?

Jagsonpal Pharmaceuticals Ltd. has 66,890,450 shares outstanding.

What happened to Jagsonpal Pharmaceuticals Ltd.’s price movement after its last earnings report?

Jagsonpal Pharmaceuticals Ltd. reported an EPS of ₹1.64 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5.029%.

Which hedge fund is a major shareholder of Jagsonpal Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in IN:JAGSNPHARM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Jagsonpal Pharmaceuticals Ltd.

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.